Dr. Postow on FDA Approval of Cemiplimab in Metastatic Cutaneous Squamous Cell Carcinoma

Video

In Partnership With:

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of cemiplimab in patients with advanced or metastatic cutaneous squamous cell carcinoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of cemiplimab in patients with advanced or metastatic cutaneous squamous cell carcinoma.

Related Videos
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Related Content
Udai Kammula, MD, FACS

Uveal Melanoma Immunogenomic Score Shows Predictive Potential

April 23rd 2024
Article
Saad Z. Usmani, MD, MBA, FACP, FASCO, hematologist-oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center

FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy

April 22nd 2024
Podcast
Saad Z. Usmani, MD, MBA, FACP, FASCO, of Memorial Sloan Kettering Cancer Center

Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma

April 22nd 2024
Article
Jeffrey S. Weber, MD, PhD

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

November 6th 2023
Podcast
James Isaacs, MD, of Cleveland Clinic

Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

April 10th 2024
Article
Melanoma

Dual Checkpoint Inhibition Leads to Higher Response Rates vs Anti-PD1 Therapy in High-Risk Resectable Melanoma

April 9th 2024
Article